This study was run to evaluate whether provider specialty is a driver for biosimilar adoption, defined as adoption probability difference (APD).
Diane Faraone, PharmD, Russell Robbins, MD, MBA, Grace Kane, MS, Douglas Londono, PhD.
The US biologics market has significantly expanded in recent years; projected to reach $62 billion in prescription drug spend by 2025. Biosimilar approvals have outpaced healthcare provider (HCP) adoption with goals to increase competition, reduce cost, and improve access highlighting needed focus for HCP awareness and real-world data explaining variation.
We analyzed patient distribution by HCP specialty and sub-specialty using NPI specialty taxonomy for each cohort with pairwise provider comparisons.
